• Consensus Rating: Buy
  • Consensus Price Target: $259.33
  • Forecasted Upside: 3.92%
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
▼ -4.63 (-1.82%)

This chart shows the closing price for SYK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Stryker Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYK

Analyst Price Target is $259.33
▲ +3.92% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Stryker in the last 3 months. The average price target is $259.33, with a high forecast of $295.00 and a low forecast of $205.00. The average price target represents a 3.92% upside from the last price of $249.54.

This chart shows the closing price for SYK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 18 polled investment analysts is to buy stock in Stryker. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 13 buy ratings
  • 8 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/25/2023KeyCorpInitiated CoverageSector Weight ➝ Sector WeightLow
1/9/2023Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$240.00 ➝ $284.00Low
1/6/2023Morgan StanleyBoost TargetEqual Weight$220.00 ➝ $260.00Low
1/4/2023BarclaysBoost Target$257.00 ➝ $265.00Low
1/3/2023Evercore ISIBoost Target$265.00Low
12/21/2022BTIG ResearchBoost Target$232.00 ➝ $268.00Low
12/20/2022Truist FinancialBoost TargetHold$230.00 ➝ $252.00Low
12/14/2022CowenBoost Target$233.00 ➝ $283.00Low
12/14/2022CowenBoost Target$233.00 ➝ $283.00Low
12/12/2022Wells Fargo & CompanyBoost TargetOverweight$248.00 ➝ $281.00Low
12/12/2022CitigroupBoost Target$249.00 ➝ $282.00Low
12/1/2022BarclaysBoost TargetOverweight$239.00 ➝ $257.00Low
11/4/2022Truist FinancialBoost Target$230.00Low
11/1/2022Royal Bank of CanadaLower TargetSector Perform$255.00 ➝ $240.00Low
11/1/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$225.00 ➝ $220.00Low
11/1/2022Wells Fargo & CompanyBoost TargetOverweight$237.00 ➝ $248.00Low
11/1/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$225.00 ➝ $220.00Low
10/17/2022BarclaysInitiated CoverageOverweight$239.00Low
10/17/2022BTIG ResearchLower TargetBuy$238.00 ➝ $232.00Low
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$270.00Low
10/10/2022Piper SandlerLower Target$260.00 ➝ $250.00N/A
10/5/2022CitigroupLower Target$255.00 ➝ $246.00Low
9/14/2022Piper SandlerBoost TargetOverweight$250.00 ➝ $260.00Low
9/6/2022BTIG ResearchLower TargetBuy$244.00 ➝ $238.00Low
7/28/2022Edward JonesUpgradeHold ➝ BuyLow
7/27/2022Truist FinancialBoost TargetOutperform$220.00Low
7/27/2022Robert W. BairdLower TargetOutperform ➝ Outperform$297.00 ➝ $240.00Low
7/27/2022Piper SandlerLower TargetOverweight$290.00 ➝ $250.00Low
7/22/2022Truist FinancialLower Target$213.00Low
7/22/2022CowenLower TargetOutperform$305.00 ➝ $233.00Low
7/21/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$285.00 ➝ $205.00Low
7/18/2022BTIG ResearchLower TargetBuy$278.00 ➝ $244.00Low
7/18/2022Stifel NicolausLower Target$285.00 ➝ $245.00Low
7/15/2022Morgan StanleyLower TargetEqual Weight$270.00 ➝ $220.00Low
7/11/2022Bank of AmericaDowngradeBuy ➝ NeutralN/A
5/17/2022CitigroupLower Target$310.00 ➝ $280.00N/A
5/2/2022Truist FinancialLower Target$296.00 ➝ $280.00Low
4/29/2022Piper SandlerLower Target$315.00 ➝ $290.00High
4/18/2022BTIG ResearchBoost Target$273.00 ➝ $278.00Low
4/12/2022Truist FinancialInitiated CoverageHold$296.00Low
3/16/2022Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$288.00 ➝ $295.00Medium
3/15/2022Evercore ISIReiterated RatingOutperform$284.00High
3/1/2022Bank of AmericaInitiated CoverageBuy ➝ BuyHigh
1/31/2022Morgan StanleyLower TargetEqual Weight$305.00 ➝ $275.00Low
1/28/2022SVB LeerinkLower TargetOutperform$300.00 ➝ $285.00High
1/28/2022BTIG ResearchLower TargetBuy$280.00 ➝ $273.00High
1/28/2022CitigroupLower Target$300.00 ➝ $290.00High
1/7/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$305.00High
1/4/2022Piper SandlerUpgradeNeutral ➝ Overweight$250.00 ➝ $315.00High
12/9/2021Royal Bank of CanadaInitiated CoverageSector Perform$278.00Low
12/6/2021Loop CapitalInitiated CoverageBuy$305.00High
11/19/2021Morgan StanleyBoost TargetOverweight$295.00 ➝ $305.00High
10/29/2021Robert W. BairdReiterated RatingBuy$301.00Medium
10/29/2021Piper SandlerBoost TargetNeutral$250.00 ➝ $255.00High
10/22/2021SVB LeerinkReiterated RatingOutperformMedium
9/14/2021Raymond JamesInitiated CoverageMarket PerformMedium
7/29/2021ArgusBoost TargetBuy$280.00 ➝ $320.00Low
7/28/2021Truist FinancialBoost TargetHold$250.00 ➝ $275.00Medium
7/28/2021Morgan StanleyBoost TargetOverweight$280.00 ➝ $300.00Low
7/28/2021SVB LeerinkBoost TargetOutperform$290.00 ➝ $300.00Low
7/28/2021Credit Suisse GroupBoost TargetOutperform$291.00 ➝ $311.00Low
7/28/2021OppenheimerBoost TargetMarket Perform$273.00 ➝ $288.00Low
7/28/2021Northland SecuritiesUpgradeMarket Perform ➝ Outperform$248.00 ➝ $310.00Low
7/28/2021Needham & Company LLCReiterated RatingHoldMedium
7/28/2021Robert W. BairdBoost TargetOutperform$292.00 ➝ $305.00Medium
7/28/2021CitigroupBoost TargetBuy$303.00 ➝ $310.00Medium
7/28/2021Piper SandlerBoost TargetNeutral$250.00 ➝ $255.00Medium
7/20/2021SVB LeerinkReiterated RatingOutperformMedium
6/28/2021Credit Suisse GroupReiterated RatingBuy$291.00Low
6/1/2021Evercore ISIUpgradeIn-Line ➝ Outperform$260.00 ➝ $285.00High
5/24/2021BarclaysInitiated CoverageUnderweight$280.00Low
4/28/2021OppenheimerBoost Target$240.00 ➝ $273.00High
4/28/2021Truist FinancialBoost Target$245.00 ➝ $255.00High
4/28/2021CitigroupBoost Target$264.00 ➝ $303.00High
4/28/2021Morgan StanleyBoost TargetOverweight$265.00 ➝ $280.00Medium
4/28/2021Wells Fargo & CompanyBoost TargetOverweight$265.00 ➝ $300.00High
4/28/2021Raymond JamesBoost TargetOutperform$255.00 ➝ $290.00Medium
4/28/2021CowenBoost TargetOutperform$255.00 ➝ $279.00High
4/28/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$251.00 ➝ $285.00High
4/28/2021Robert W. BairdBoost TargetOutperform$265.00 ➝ $292.00High
2/24/2021JPMorgan Chase & Co.Boost TargetOverweight$245.00 ➝ $265.00Low
1/28/2021Credit Suisse GroupLower TargetOutperform ➝ Outperform$278.00 ➝ $273.00Low
1/28/2021Morgan StanleyLower TargetOverweight$272.00 ➝ $265.00High
1/28/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$228.00 ➝ $251.00Low
1/28/2021Raymond JamesBoost TargetOutperform$240.00 ➝ $255.00Low
1/28/2021Needham & Company LLCReiterated RatingHoldLow
1/6/2021Truist FinancialBoost Target$210.00 ➝ $245.00N/A
1/6/2021Credit Suisse GroupBoost TargetOutperform$253.00 ➝ $278.00N/A
1/4/2021GuggenheimInitiated CoverageNeutralN/A
12/31/2020BTIG ResearchBoost TargetBuy$234.00 ➝ $252.00N/A
12/15/2020Morgan StanleyBoost TargetOverweight$225.00 ➝ $272.00Low
11/12/2020Robert W. BairdBoost TargetOutperform$243.00 ➝ $258.00Low
10/30/2020Smith Barney CitigroupBoost Target$232.00 ➝ $240.00High
10/30/2020SVB LeerinkBoost TargetOutperform$225.00 ➝ $235.00High
10/30/2020Credit Suisse GroupBoost TargetOutperform$243.00 ➝ $253.00High
10/12/2020Raymond JamesBoost TargetOutperform$220.00 ➝ $240.00Medium
10/6/2020Northland SecuritiesInitiated CoverageMarket Perform$225.00Medium
9/28/2020Wells Fargo & CompanyBoost TargetOverweight$222.00 ➝ $232.00Medium
9/11/2020Wolfe ResearchInitiated CoverageMarket Perform$230.00Low
7/31/2020UBS GroupBoost TargetNeutral$202.00 ➝ $215.00High
7/31/2020Morgan StanleyBoost TargetOverweight$215.00 ➝ $225.00Low
7/31/2020SVB LeerinkBoost TargetOutperform$215.00 ➝ $225.00Medium
7/31/2020Credit Suisse GroupBoost TargetOutperform$237.00 ➝ $243.00High
7/31/2020Needham & Company LLCReiterated RatingHoldMedium
7/31/2020OppenheimerReiterated RatingHold$215.00Medium
7/31/2020CitigroupBoost TargetBuy$227.00 ➝ $232.00Medium
7/15/2020SVB LeerinkReiterated RatingOutperformLow
5/11/2020ArgusLower TargetBuy$240.00 ➝ $230.00Low
5/1/2020CitigroupBoost TargetBuy$200.00 ➝ $215.00Medium
5/1/2020CfraLower TargetStrong-Buy$234.00 ➝ $231.00Low
5/1/2020Wells Fargo & CompanyBoost TargetOverweight$201.00 ➝ $205.00Medium
5/1/2020Morgan StanleyBoost TargetOverweight$210.00 ➝ $215.00High
5/1/2020Stifel NicolausBoost TargetBuy$145.00 ➝ $205.00High
5/1/2020UBS GroupLower TargetNeutral$230.00 ➝ $202.00High
5/1/2020OppenheimerReiterated RatingHold$200.00Medium
5/1/2020Credit Suisse GroupBoost TargetOutperform$229.00 ➝ $237.00Medium
5/1/2020Deutsche Bank AktiengesellschaftLower TargetBuy$243.00 ➝ $228.00High
4/22/2020CowenLower TargetOutperform$240.00 ➝ $220.00Low
4/15/2020JPMorgan Chase & Co.Lower TargetOverweight$240.00 ➝ $210.00Medium
4/13/2020Raymond JamesLower TargetOutperform$240.00 ➝ $205.00High
4/13/2020BarclaysDowngradeEqual Weight ➝ Underweight$155.00High
4/1/2020Wells Fargo & CompanyLower TargetOverweight$243.00 ➝ $201.00Medium
4/1/2020The Goldman Sachs GroupDowngradeBuy ➝ Sell$248.00 ➝ $150.00High
3/27/2020Morgan StanleyLower TargetOverweight$250.00 ➝ $210.00Low
3/27/2020CitigroupLower TargetBuy$235.00 ➝ $200.00Medium
3/25/2020Credit Suisse GroupLower TargetOutperform$247.00 ➝ $162.00Low
3/24/2020Stifel NicolausLower TargetBuy$250.00 ➝ $145.00High
3/6/2020Credit Suisse GroupLower TargetOutperform$255.00 ➝ $247.00Low
3/4/2020CitigroupInitiated CoverageBuy$235.00High
2/12/2020The Goldman Sachs GroupInitiated CoverageBuy$248.00Low
1/30/2020BTIG ResearchReiterated RatingBuyMedium
1/29/2020Cantor FitzgeraldReiterated RatingNeutralMedium
1/29/2020Stifel NicolausBoost TargetBuy$245.00 ➝ $250.00Low
1/29/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$239.00 ➝ $243.00Low
1/29/2020Robert W. BairdBoost TargetOutperform$242.00 ➝ $248.00High
1/29/2020Morgan StanleyBoost TargetOverweight$242.00 ➝ $250.00High
1/7/2020SunTrust BanksInitiated CoverageHold$217.00Low
1/7/2020Piper SandlerDowngradeOverweight ➝ Neutral$210.00Low
1/7/2020Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$210.00Medium
1/3/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy$179.00Low
1/2/2020Evercore ISIUpgradeIn-Line ➝ OutperformLow
12/30/2019BTIG ResearchBoost TargetBuy$228.00 ➝ $236.00Low
12/17/2019Morgan StanleyBoost TargetOverweight$230.00 ➝ $242.00High
11/5/2019BarclaysDowngradeOverweight ➝ Equal Weight$226.00 ➝ $207.00High
10/30/2019Robert W. BairdBoost TargetOutperform$239.00 ➝ $242.00Medium
10/30/2019Bank of AmericaBoost TargetBuy$220.00 ➝ $245.00High
9/5/2019BTIG ResearchSet TargetBuy$228.00Medium
9/4/2019Piper Jaffray CompaniesReiterated RatingBuyLow
7/29/2019BTIG ResearchReiterated RatingBuy$228.00Low
7/26/2019Raymond JamesSet TargetBuy$240.00Low
7/26/2019Royal Bank of CanadaSet TargetBuy$220.00Low
7/26/2019BMO Capital MarketsSet TargetHold$216.00Low
7/26/2019BarclaysSet TargetBuy$226.00N/A
7/26/2019Robert W. BairdBoost TargetOutperform$206.00 ➝ $239.00Low
7/26/2019Credit Suisse GroupBoost TargetOutperform$232.00 ➝ $237.00Low
7/26/2019Cantor FitzgeraldBoost TargetNeutral$190.00 ➝ $230.00High
7/26/2019Piper Jaffray CompaniesBoost TargetOverweight$205.00 ➝ $240.00High
7/16/2019Morgan StanleyBoost TargetOverweight$218.00 ➝ $230.00Low
7/15/2019BTIG ResearchBoost TargetBuy ➝ Positive$219.00Medium
7/11/2019Credit Suisse GroupBoost TargetOutperform$200.00 ➝ $232.00Low
7/10/2019SVB LeerinkReiterated RatingOutperformLow
7/2/2019Wells Fargo & CompanyBoost TargetOutperform$219.00 ➝ $228.00Low
4/24/2019OppenheimerBoost TargetOutperform$183.00 ➝ $192.00Low
4/24/2019Robert W. BairdBoost TargetOutperform ➝ Outperform$201.00 ➝ $206.00Low
4/24/2019Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$181.00 ➝ $208.00Low
4/24/2019Cantor FitzgeraldBoost TargetNeutral ➝ Neutral$175.00 ➝ $190.00Low
4/15/2019BarclaysBoost TargetOverweight ➝ Overweight$203.00 ➝ $211.00Low
4/1/2019Wells Fargo & CompanyBoost TargetOutperform$214.00 ➝ $219.00Low
3/19/2019JPMorgan Chase & Co.Boost TargetOverweight$200.00 ➝ $215.00Medium
3/18/2019BTIG ResearchBoost TargetBuy$211.00Low
3/11/2019Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$184.00 ➝ $204.00Medium
3/8/2019BarclaysSet TargetBuy$203.00Low
3/4/2019Morgan StanleyBoost TargetOverweight ➝ Overweight$200.00 ➝ $218.00Low
3/1/2019Piper Jaffray CompaniesReiterated RatingOverweight$205.00Medium
2/4/2019SunTrust BanksBoost TargetBuy ➝ Positive$205.00Low
1/31/2019Credit Suisse GroupUpgradeOutperformMedium
1/18/2019Cantor FitzgeraldReiterated RatingNeutralMedium
1/2/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$179.00Medium
1/2/2019Morgan StanleyLower TargetOverweight ➝ Overweight$212.00 ➝ $197.00Low
1/2/2019CitigroupLower TargetNeutral ➝ Neutral$174.00 ➝ $169.00Low
1/2/2019Evercore ISIUpgradeIn-Line ➝ Outperform$156.75Medium
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$195.00Low
11/27/2018UBS GroupInitiated CoverageNeutral$180.00 ➝ $180.00High
11/15/2018CitigroupBoost TargetNeutral ➝ Neutral$173.00 ➝ $174.00Medium
11/9/2018OppenheimerSet TargetHold$170.00N/A
11/9/2018CowenSet TargetBuy$195.00Low
11/9/2018Needham & Company LLCReiterated RatingHoldLow
10/26/2018OppenheimerSet TargetHold$170.00Medium
10/15/2018BarclaysInitiated CoverageOverweight ➝ Overweight$198.00High
9/13/2018JPMorgan Chase & Co.Boost TargetOverweight$200.00Medium
9/12/2018BTIG ResearchReiterated RatingBuy$187.00Low
9/11/2018Needham & Company LLCReiterated RatingHoldLow
8/16/2018BTIG ResearchInitiated CoverageBuy$187.00Medium
7/25/2018OppenheimerSet TargetHold$170.00Medium
7/25/2018Robert W. BairdBoost TargetOutperform ➝ Outperform$187.00 ➝ $192.00Medium
7/25/2018CitigroupBoost TargetNeutral ➝ Neutral$171.00 ➝ $173.00High
7/25/2018Cantor FitzgeraldBoost TargetNeutral ➝ Neutral$170.00 ➝ $175.00High
7/25/2018Royal Bank of CanadaReiterated RatingBuy$184.00High
7/25/2018Needham & Company LLCReiterated RatingHoldHigh
7/12/2018BMO Capital MarketsReiterated RatingHold$174.00Low
6/27/2018Sanford C. BernsteinInitiated CoverageMarket Perform$177.00Medium
6/13/2018Cantor FitzgeraldReiterated RatingHold$170.00Low
5/1/2018CitigroupBoost TargetNeutral ➝ Neutral$166.00 ➝ $171.00Low
4/27/2018BMO Capital MarketsBoost TargetMarket Perform$170.00Medium
4/27/2018Stifel NicolausBoost TargetBuy ➝ Buy$183.00 ➝ $187.00Low
4/27/2018Cantor FitzgeraldReiterated RatingHold ➝ NeutralHigh
4/2/2018Evercore ISIInitiated CoverageIn-Line$165.00Medium
3/15/2018Raymond JamesInitiated CoverageOutperform$183.00Low
2/27/2018CitigroupUpgradeSell ➝ Neutral$165.77 ➝ $166.00Medium
2/26/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$179.00 ➝ $186.00High
2/1/2018OppenheimerReiterated RatingHold$165.00Low
2/1/2018CitigroupReiterated RatingMarket Perform$156.00 ➝ $165.00Low
1/31/2018GuggenheimReiterated RatingBuyLow
1/31/2018Piper Jaffray CompaniesReiterated RatingBuy$170.00Low
1/31/2018Needham & Company LLCReiterated RatingHoldMedium
1/31/2018SVB LeerinkBoost TargetOutperform ➝ Outperform$177.00 ➝ $184.00Low
(Data available from 1/31/2018 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 23 positive mentions
  • 8 negative mentions
  • 2 very negative mentions
  • 2 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
  • 9 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 12 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 14 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 2 very negative mentions

Current Sentiment

  • 14 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Stryker logo
Stryker Corp. operates as a medical technology company. It operates through the following segments: Orthopaedics & Spine and MedSurg & Neurotechnology. The Orthopaedics & Spine segment provides implants for use in total joint replacements, such as hip, knee, and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that are used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, patient & caregiver safety technologies, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques, products for brain and open skull based surgical procedures, orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products, minimally invasive products fo
Read More

Today's Range

Now: $249.54
Low: $249.27
High: $254.16

50 Day Range

MA: $245.76
Low: $224.65
High: $263.81

52 Week Range

Now: $249.54
Low: $188.84
High: $279.28


1,209,465 shs

Average Volume

1,341,709 shs

Market Capitalization

$94.43 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Stryker?

The following sell-side analysts have issued reports on Stryker in the last year: Bank of America Co., Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Cowen Inc, Cowen Inc., Deutsche Bank Aktiengesellschaft, Edward Jones, Evercore ISI, Jefferies Financial Group Inc., KeyCorp, Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, StockNews.com, TheStreet, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for SYK.

What is the current price target for Stryker?

18 Wall Street analysts have set twelve-month price targets for Stryker in the last year. Their average twelve-month price target is $259.33, suggesting a possible upside of 3.9%. Sanford C. Bernstein has the highest price target set, predicting SYK will reach $295.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $205.00 for Stryker in the next year.
View the latest price targets for SYK.

What is the current consensus analyst rating for Stryker?

Stryker currently has 7 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SYK will outperform the market and that investors should add to their positions of Stryker.
View the latest ratings for SYK.

What other companies compete with Stryker?

How do I contact Stryker's investor relations team?

Stryker's physical mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company's listed phone number is (269) 385-2600 and its investor relations email address is [email protected] The official website for Stryker is www.strykercorp.com. Learn More about contacing Stryker investor relations.